Sharp A, Jackson R, Cornforth C, et al. - In order to appraise the value of angiogenic biomarkers for predicting adverse pregnancy outcome in severe early-onset fetal growth restriction (FGR), researchers conducted a secondary analysis of the multicentre, placebo-controlled STRIDER UK randomized controlled trial of singleton pregnancies with severe early-onset fetal growth restriction. Either sildenafil 25 mg three times daily or placebo was provided to women with FGR pregnancies between 22⁺⁰ and 29⁺⁶ weeks of gestation until 32⁺⁰ weeks’ gestation or delivery. Based upon maternal demographics (age, parity, blood pressure, preeclampsia, gestational hypertension), fetal biometric (estimated fetal weight) and Doppler measurements (Middle Cerebral Artery, Umbilical Artery) and maternal angiogenic biomarkers [placental growth factor (PlGF), soluble endoglin, soluble fms-like tyrosine kinase 1 (sFlt-1) and sFlt-1:PlGF ratio], they developed prediction models. As per multivariate regression analysis, estimated fetal weight (EFW) and sFlt-1:PlGF were independent predictors of livebirth and overall survival. Findings thereby suggest that a model involving EFW and sFlt-1:PlGF ratio could assist in predicting livebirth and overall survival in severe early-onset FGR pregnancies.